Liver Disease in Europe Has Reached a Tipping Point

Every day, nearly 780 people across Europe die from cirrhosis or liver cancer. A major new report from the EASL–Lancet Commission, published in April 2026, makes the scale of the problem impossible to ignore. Cirrhosis and liver cancer together claim around 284,000 lives across the WHO European Region each year. Most of those deaths were preventable.

Furthermore, this liver health crisis runs against the grain of wider progress. Europe has made genuine headway against heart disease and many cancers over recent decades. Yet liver disease remains one of the very few major non-communicable diseases (NCDs) still moving in the wrong direction.

The Numbers Driving the Liver Health Crisis

The scale of liver disease in Europe deserves to be stated plainly.

Liver cancer mortality has surged by more than 50% since 2000. Deaths rose from around 43,000 per year to approximately 69,000 in 2023. Moreover, the economic toll is enormous. Without liver disease, EU economies and associated European states would be around €55 billion larger each year. In addition, liver disease reduces GDP by roughly 0.3% across the region. That figure reflects premature death, lost productivity, and prolonged workforce absence.

Dr Hans Kluge, WHO Regional Director for Europe, was direct: “Cirrhosis and liver cancer cause nearly 780 deaths every day in the WHO European Region, around 3% of all deaths. Tackling the shared risk factors, including alcohol, unhealthy diets, and viral hepatitis, must be part of the broader NCD response.”

What Is Driving This Crisis?

The report, titled From Evidence to Impact: Implementing Sustainable Liver Health in Europe, shows that liver disease in Europe does not arise in a vacuum. Alcohol consumption, obesity, and viral hepatitis are the principal causes. Together, they account for the vast majority of liver-related deaths in the region.

The rise of metabolic dysfunction-associated steatotic liver disease (MASLD) is particularly concerning. Unhealthy diets and excess weight are fuelling its spread. Furthermore, the Commission points squarely at commercial forces as key contributors to this liver health crisis. The marketing, pricing, and ready availability of alcohol and ultra-processed foods are all part of the picture.

Consequently, the report’s modelling carries real weight. Eliminating behavioural risk factors alone could almost halve the burden of liver disease. It would also reduce cardiovascular disease, diabetes, and certain cancers at the same time.

Prof. Tom H. Karlsen, Commission Co-Chair, put it clearly: “Europe has the knowledge and tools to prevent much of this burden. The real challenge now is implementation.”

Liver Disease in Europe Is Still Caught Too Late

One of the most urgent findings concerns timing. Doctors still diagnose liver disease in Europe overwhelmingly at an advanced stage. By that point, treatment options narrow and outcomes worsen sharply. Earlier detection would change that picture significantly.

The Commission therefore calls for better integrated care pathways. It wants stronger links between primary care, specialist services, and community settings. This matters especially because many people with liver disease also manage multiple other health conditions.

Marko Korenjak, President of the European Liver Patients Association (ELPA), was frank: “Too many people across Europe are still being diagnosed too late. The Commission’s recommendations reflect what patients and their families have been asking for. We urge policymakers to move from words to action.”

What Governments Must Now Do

Addressing liver disease in Europe will require action on several fronts. First, governments should introduce health warning labels on alcohol products and restrict digital marketing, particularly aimed at young people. Second, stronger regulation of alcohol and ultra-processed food marketing and taxation is essential. Third, viral hepatitis testing must expand, especially for migrants and underserved communities.

Beyond that, the Commission calls for better integrated care models across health services, and for liver health to be embedded in national NCD strategies. It also wants EU Member States to pursue joint procurement of affordable medicines. Additionally, liver health metrics should be included in existing NCD monitoring frameworks.

Prevention, as the Commission makes clear, also makes strong economic sense. Better screening, earlier treatment, and structural policy changes would together deliver significant returns, both in lives saved and in economic output protected.

A Window of Opportunity Europe Cannot Afford to Miss

Prof. Debbie Shawcross, EASL Secretary General, summed up the moment clearly: “Liver disease is a growing public health failure that we have the tools to prevent. What is missing is not evidence, but action.”

The Commission sets out three priorities. To begin with, governments must make liver disease a genuine top health priority and include it in national and European health plans. Next, they must detect and treat the disease earlier, with joined-up care for those managing multiple conditions. Finally, they must tackle the root causes, including alcohol, unhealthy food, and the commercial interests that make harmful products so accessible.

The liver health crisis gripping Europe is not inevitable. The evidence is there. The policy tools exist. Therefore, what Europe now needs is the political will to use them.

The EASL–Lancet Commission on Liver Health in Europe brings together leading experts in hepatology, public health, economics, patient advocacy, and health policy. Its second report was published in April 2026.

Source: dbrecoveryresources